EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Next-generation cancer vaccines and emerging immunotherapy combinations

Anne Brandenburg, Annkristin Heine, Peter Brossart

Trends in Cancer · 2024

DOI: 10.1016/j.trecan.2024.06.003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2024. Verfasst von Anne Brandenburg und 2 weiteren Autor:innen. Beteiligte Einrichtung: Medical Clinic III of Oncology, Hematology, Rheumatology and Immune-Oncology, University Hospital Bonn, Venusberg Campus 1, 53127 Bonn, Germany. Hauptthemen laut MEDLINE: Cancer Vaccines, Neoplasms, Immune Checkpoint Inhibitors, Immunotherapy. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 171 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic cancer vaccines have been a subject of research for several decades as potential new weapons to tackle malignancies. Their goal is to induce a long-lasting and efficient antitumour-directed immune response, capable of mediating tumour regression, preventing tumour progression, and eradicating minimal residual disease, while avoiding major adverse effects. Development of new vaccine technologies and antigen prediction methods has led to significant improvements in cancer vaccine efficacy. However, for their successful clinical application, certain obstacles still need to be overcome, especially tumour-mediated immunosuppression and escape mechanisms. In this review, we introduce therapeutic cancer vaccines and subsequently discuss combination approaches of next-generation cancer vaccines and existing immunotherapies, particularly immune checkpoint inhibitors (ICIs) and adoptive cell transfer/cell-based immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesNeoplasmsImmune Checkpoint InhibitorsImmunotherapyHumansAnimalsAntigens, NeoplasmImmunotherapy, AdoptiveCombined Modality TherapyAdoptive Transfer

Stichwörter der Autor:innen

CAR-T cellscancer vaccinesimmune checkpointsimmunotherapy combination

Substanzen

Cancer VaccinesImmune Checkpoint InhibitorsAntigens, Neoplasm

Autor:innen und Institutionen

  • Medical Clinic III of Oncology, Hematology, Rheumatology and Immune-Oncology, University Hospital Bonn, Venusberg Campus 1, 53127 Bonn, Germany.
  • Medical Clinic III of Oncology, Hematology, Rheumatology and Immune-Oncology, University Hospital Bonn, Venusberg Campus 1, 53127 Bonn, Germany. Electronic address: Peter.Brossart@ukbonn.de.

Zitieren

APA

Brandenburg, A., Heine, A., & Brossart, P. (2024). Next-generation cancer vaccines and emerging immunotherapy combinations. Trends in Cancer. https://doi.org/10.1016/j.trecan.2024.06.003

Vancouver

Brandenburg A, Heine A, Brossart P. Next-generation cancer vaccines and emerging immunotherapy combinations. Trends in Cancer. 2024. doi:10.1016/j.trecan.2024.06.003

BibTeX
@article{Brandenburg2024,
  author = {Brandenburg, Anne and Heine, Annkristin and Brossart, Peter},
  title = {Next-generation cancer vaccines and emerging immunotherapy combinations},
  journal = {Trends in Cancer},
  year = {2024},
  doi = {10.1016/j.trecan.2024.06.003}
}
Kostenlos starten →